Approval · Notice of Compliance 38437 · 2026
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION: Notice of Compliance 38437
Issued October 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38437
- Date
- October 9, 2026
- Company
- Dr Reddys Laboratories Ltd
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- CAELYX
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE FOR INJECTION | Not yet assigned | — |
Medicinal ingredients
- DOXORUBICIN HYDROCHLORIDE 2 MG per ML